Background: Sacubitril/valsartan, has been found to be more beneficial than enalapril for reducing the incidences of sudden cardiac death, death from worsening heart failure (HF), and hospitalization. However, there is no prospective echocardiographic data describing the effects of sacubitril/valsartan on the heart functions and left ventricular (LV) reverse remodeling. Therefore, the aim of our study was to evaluate the effects of sacubitril/valsartan on the LV functions using two dimensional (2D), three dimensional (3D) echocardiography and the 3D strain parameters. Methods: In 100 patients with HF with reduced ejection fraction (HRrEF) who have indications for the use of sacubitril/valsartan as recommended by recent guidelines were prospectively enrolled. The basal 2D and 3D echocardiographic parameters were compared to those obtained 3 months after starting the sacubitril/valsartan treatment.
Study Type
OBSERVATIONAL
Enrollment
100
Basal two dimensional and three dimensional echocardiographic parameters were compared to those obtained 3 months after starting the sacubitril/valsartan treatment
Two dimensional left ventricular ejection fraction
Two dimensional ejection fraction is measured as baseline and after 3 months follow-up
Time frame: 3 months
Three dimensional left ventricular ejection fraction
Three dimensional ejection fraction is measured as baseline and after 3 months follow-up
Time frame: 3 months
Two dimensional left ventricular volumes
Two dimensional left ventricular volumes are measured as baseline and after 3 months follow-up
Time frame: 3 months
Three dimensional left ventricular volumes
Three dimensional left ventricular volumes are measured as baseline and after 3 months follow-up
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.